-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Migraine is a chronic disease with repeated mild or severe headaches, usually accompanied by various symptoms of the autonomic nervous system
Associated symptoms may include nausea, vomiting, more sensitivity to light, more sensitivity to sounds, and physical activity can aggravate the sensation of pain
Although there are migraine prevention drugs can be used to reduce the frequency of migraine attacks, but many patients do not respond to or can not tolerate these therapies
Prevention 43% of migraine prophylactic medication patients have a history of medication failure or replacement medication
Basic research has found that calcitonin gene-related peptide (CGRP) substances have been shown to participate in the occurrence of migraine by expanding blood vessels in the brain
Calcitonin gene-related peptide (CGRP) substances have been shown to be involved in the occurrence of migraine by expanding blood vessels in the brain
The study took all consecutive adult chronic migraine patients with clinical indications of gallanizumab into consideration.
In the end, 156 patients (82.
Such patients tend to have low body mass index (BMI; P=.
They more often have a good response to triptans (p=.
In summary, factors such as unilateral pain, good response to triptans, and normal weight may be related to the relief of symptoms in patients with chronic migraine in the first three months of treatment with gallanizumab
In summary, factors such as unilateral pain, good response to triptans, and normal weight may be related to the relief of symptoms in patients with chronic migraine in the first three months of treatment with gallanizumab
references:
Rapid response to galcanezumab and predictive factors in chronic migraine patients: a 3-month observational, longitudinal, cohort multicenter Italian real-life study.
Rapid response to galcanezumab and predictive factors in chronic migraine patients: a 3-month observational, longitudinal, cohort multicenter Italian real-life study.
Leave a message here
